{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:21:58Z","timestamp":1788956518158,"version":"build-2803163510"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04213-4","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T13:18:10Z","timestamp":1769951890000},"page":"2523-2549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5192-3933","authenticated-orcid":false,"given":"Nada Khairi","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fawzi","family":"Al-Hussainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Renuka","family":"Jyothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya Priyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bethanney","family":"Janney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Polatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder Naji","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasim M.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaned","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"issue":"1","key":"4213_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the cancer dependency map. Nat Rev Cancer. 2025;25(1):59\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4213_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","volume":"23","author":"L Chen","year":"2024","unstructured":"Chen L, Xu Y-X, Wang Y-S, Ren Y-Y, Dong X-M, Wu P, et al. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer. 2024;23(1):229.","journal-title":"Mol Cancer"},{"issue":"2","key":"4213_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84(2):191\u2013206.","journal-title":"Eur Urol"},{"key":"4213_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.163","volume-title":"A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population","author":"F Karzai","year":"2018","unstructured":"Karzai F, Madan RA, Owens H, Couvillon A, Hankin A, Williams M, et al. A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. American Society of Clinical Oncology; 2018."},{"issue":"17","key":"4213_CR5","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"5","key":"4213_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"4213_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, Van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4213_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4213_CR9","first-page":"2190","volume":"5","author":"T Wei","year":"2015","unstructured":"Wei T, Zhang J, Qin Y, Wu Y, Zhu L, Lu L, et al. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Cancer Res. 2015;5(7):2190.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"4213_CR10","doi-asserted-by":"publisher","first-page":"e23849","DOI":"10.4161\/onci.23849","volume":"2","author":"K Sakuishi","year":"2013","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, et al. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849.","journal-title":"Oncoimmunology"},{"issue":"9","key":"4213_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","volume":"21","author":"W Wang","year":"2009","unstructured":"Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol. 2009;21(9):1065\u201377.","journal-title":"Int Immunol"},{"key":"4213_CR12","volume-title":"Retracted: simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models","author":"FK Kiani","year":"2022","unstructured":"Kiani FK, Izadi S, Dezfouli EA, Ebrahimi F, Mohammadi M, Chalajour H, et al. Retracted: simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Elsevier; 2022."},{"issue":"1","key":"4213_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4049\/jimmunol.1402381","volume":"195","author":"CA Fuhrman","year":"2015","unstructured":"Fuhrman CA, Yeh W-I, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol. 2015;195(1):145\u201355.","journal-title":"J Immunol"},{"key":"4213_CR14","doi-asserted-by":"publisher","first-page":"108288","DOI":"10.1016\/j.intimp.2021.108288","volume":"101","author":"M Fathi","year":"2021","unstructured":"Fathi M, Bahmanpour S, Barshidi A, Rasouli H, Kiani FK, Khesht AMS, et al. Simultaneous blockade of TIGIT and HIF-1\u03b1 induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. Int Immunopharmacol. 2021;101:108288.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4213_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/iub.2461","volume":"73","author":"M Fathi","year":"2021","unstructured":"Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, et al. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life. 2021;73(5):726\u201338.","journal-title":"IUBMB Life"},{"issue":"10","key":"4213_CR16","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/cancers13102414","volume":"13","author":"A Derakhshani","year":"2021","unstructured":"Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad MA, Rasibonab F, Safarpour H, et al. Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine. Cancers. 2021;13(10):2414.","journal-title":"Cancers"},{"key":"4213_CR17","volume-title":"Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, Wang X, Hullings M, Arauz G, Bartido S, Lewis JS, et al. Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). American Society of Clinical Oncology; 2013."},{"issue":"4","key":"4213_CR18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2004-06-2089","volume":"105","author":"A Boasso","year":"2005","unstructured":"Boasso A, Herbeuval J-P, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2, 3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood. 2005;105(4):1574\u201381.","journal-title":"Blood"},{"issue":"11","key":"4213_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ni846","volume":"3","author":"U Grohmann","year":"2002","unstructured":"Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4\u2013Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3(11):1097\u2013101.","journal-title":"Nat Immunol"},{"issue":"2","key":"4213_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000490025","volume":"47","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 2018;47(2):721\u201334.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"4213_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"JG Egen","year":"2002","unstructured":"Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3(7):611\u20138.","journal-title":"Nat Immunol"},{"issue":"2","key":"4213_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11095-022-03169-2","volume":"39","author":"AMS Kheshti","year":"2022","unstructured":"Kheshti AMS, Hajizadeh F, Barshidi A, Rashidi B, Ebrahimi F, Bahmanpour S, et al. Cell vaccine and nanoparticles loaded with interleukin-15 and anti-beta-catenin siRNA significantly inhibits cancer growth and induces anti-tumor immune response. Pharm Res. 2022;39(2):353\u201367.","journal-title":"Pharm Res"},{"key":"4213_CR23","unstructured":"Khodakarami A, Kashani MA, Nazer A, Kheshti AM, Rashidi B, Karpisheh V et al. Codelivery of Nrf 2 siRNA and cyclophosphamide inhibits leukemia progression. 2023"},{"key":"4213_CR24","doi-asserted-by":"publisher","first-page":"103868","DOI":"10.1016\/j.jddst.2022.103868","volume":"77","author":"AAH Feizi","year":"2022","unstructured":"Feizi AAH, Vakili-Samiani S, Karpisheh V, Masjedi A, Izadi S, Adibfar S, et al. Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine\/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles. J Drug Deliv Sci Technol. 2022;77:103868.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4213_CR25","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.34172\/ijdrc.2023.e2","volume":"1","author":"S Izadi","year":"2023","unstructured":"Izadi S, Hojjat-Farsangi M, Karpisheh V, Jadidi-Niaragh F. Pan cyclin-dependent kinase inhibitors for the treatment of breast cancer. Int J Drug Res Clin. 2023;1(1):e2\u2013e2.","journal-title":"Int J Drug Res Clin"},{"issue":"3","key":"4213_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):697\u2013717.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5256","key":"4213_CR27","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"23","key":"4213_CR28","first-page":"5301","volume":"58","author":"MB Mokyr","year":"1998","unstructured":"Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998;58(23):5301\u20134.","journal-title":"Cancer Res"},{"issue":"10","key":"4213_CR29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00262-005-0668-3","volume":"54","author":"MS Sabel","year":"2005","unstructured":"Sabel MS, Hess SD, Egilmez NK, Conway TF Jr., Chen F-A, Bankert RB. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother. 2005;54(10):944\u201352.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4213_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-025-03702-4","volume":"25","author":"S Abolhasani","year":"2025","unstructured":"Abolhasani S, Khodakarami A, Masjedi A, Rashidi B, Izadi S, Noukabadi FK, et al. Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1. Cancer Cell Int. 2025;25(1):1\u201314.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"4213_CR31","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","volume":"24","author":"S Slovin","year":"2013","unstructured":"Slovin S, Higano C, Hamid O, Tejwani S, Harzstark A, Alumkal J, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study. Ann Oncol. 2013;24(7):1813\u201321.","journal-title":"Ann Oncol"},{"issue":"21","key":"4213_CR32","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543\u201353.","journal-title":"Mol Cell Biol"},{"key":"4213_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-89","volume":"11","author":"S Wada","year":"2013","unstructured":"Wada S, Jackson CM, Yoshimura K, Yen H-R, Getnet D, Harris TJ, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:1\u201314.","journal-title":"J Transl Med"},{"key":"4213_CR34","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"4213_CR35","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4213_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025;87(3):302\u201313.","journal-title":"Eur Urol"},{"issue":"6","key":"4213_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877\u201392.","journal-title":"Eur Urol Oncol"},{"key":"4213_CR38","first-page":"29","volume":"27","author":"TB Murray","year":"2021","unstructured":"Murray TB. The pathogenesis of prostate cancer. Exon Public. 2021;27:29\u201341.","journal-title":"Exon Public"},{"issue":"9","key":"4213_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/09553000903043059","volume":"85","author":"S Chopra","year":"2009","unstructured":"Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, M\u00e9nard C, et al. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol. 2009;85(9):805\u201313.","journal-title":"Int J Radiat Biol"},{"key":"4213_CR40","doi-asserted-by":"crossref","unstructured":"Siddiqui S, Puranik SI, Akbar A, Ghagane SC. Genetic polymorphism and prostate cancer: an update. In: Genetic polymorphisms-new insights. IntechOpen. 2021.","DOI":"10.5772\/intechopen.99483"},{"issue":"13","key":"4213_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMe0901166","volume":"360","author":"MJ Barry","year":"2009","unstructured":"Barry MJ. Screening for prostate cancer\u2013the controversy that refuses to die. N Engl J Med. 2009;360(13):1351.","journal-title":"N Engl J Med"},{"issue":"1","key":"4213_CR42","first-page":"5324600","volume":"2022","author":"S Mirmoeeni","year":"2022","unstructured":"Mirmoeeni S, Azari Jafari A, Shah M, Salemi F, Hashemi SZ, Seifi A. The clinical, diagnostic, therapeutic, and prognostic characteristics of brain metastases in prostate cancer: a systematic review. Prostate Cancer. 2022;2022(1):5324600.","journal-title":"Prostate Cancer"},{"issue":"2","key":"4213_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imm.13456","volume":"168","author":"D Feng","year":"2023","unstructured":"Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023;168(2):199\u2013202.","journal-title":"Immunology"},{"issue":"6","key":"4213_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccell.2021.05.016","volume":"39","author":"MO Li","year":"2021","unstructured":"Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, et al. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39(6):725\u20139.","journal-title":"Cancer Cell"},{"issue":"15","key":"4213_CR45","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.7150\/thno.84947","volume":"13","author":"Q Lin","year":"2023","unstructured":"Lin Q, Choyke PL, Sato N. Visualizing vasculature and its response to therapy in the tumor microenvironment. Theranostics. 2023;13(15):5223.","journal-title":"Theranostics"},{"issue":"1","key":"4213_CR46","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/13880209.2019.1672753","volume":"57","author":"H-D Cho","year":"2019","unstructured":"Cho H-D, Kim J-H, Park J-K, Hong S-M, Kim D-H, Seo K-I. Kochia scoparia seed extract suppresses VEGF-induced angiogenesis via modulating VEGF receptor 2 and PI3K\/AKT\/mTOR pathways. Pharm Biol. 2019;57(1):684\u201393.","journal-title":"Pharm Biol"},{"issue":"4","key":"4213_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3892\/etm.2023.12182","volume":"26","author":"C Ene","year":"2023","unstructured":"Ene C, Nicolae I, Ene CD. Angiogenic systemic response to the hypoxic microenvironment in prostate tumorigenesis: a pilot study. Exp Ther Med. 2023;26(4):483.","journal-title":"Exp Ther Med"},{"issue":"12","key":"4213_CR48","doi-asserted-by":"publisher","first-page":"153247","DOI":"10.1016\/j.prp.2020.153247","volume":"216","author":"V Karpisheh","year":"2020","unstructured":"Karpisheh V, Joshi N, Zekiy AO, Beyzai B, Hojjat-Farsangi M, Namdar A, et al. EP4 receptor as a novel promising therapeutic target in colon cancer. Pathol Res Pract. 2020;216(12):153247.","journal-title":"Pathol Res Pract"},{"key":"4213_CR49","doi-asserted-by":"publisher","first-page":"106338","DOI":"10.1016\/j.prostaglandins.2019.106338","volume":"144","author":"V Karpisheh","year":"2019","unstructured":"Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, et al. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins Other Lipid Mediat. 2019;144:106338.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"4213_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12935-022-02660-5","volume":"22","author":"A Khodakarami","year":"2022","unstructured":"Khodakarami A, Adibfar S, Karpisheh V, Abolhasani S, Jalali P, Mohammadi H, et al. The molecular biology and therapeutic potential of Nrf2 in leukemia. Cancer Cell Int. 2022;22(1):241.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"4213_CR51","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41417-022-00454-5","volume":"29","author":"L Fang","year":"2022","unstructured":"Fang L, Li D, Yin J, Pan H, Ye H, Bowman J, et al. TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence. Cancer Gene Ther. 2022;29(10):1463\u201376.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"4213_CR52","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1002\/jcb.29664","volume":"121","author":"S Fu","year":"2020","unstructured":"Fu S, Liu T, Lv C, Fu C, Zeng R, Kakehi Y, et al. Stromal-epithelial interactions in prostate cancer: overexpression of PAGE4 in stromal cells inhibits the invasive ability of epithelial cells. J Cell Biochem. 2020;121(11):4406\u201318.","journal-title":"J Cell Biochem"},{"issue":"16","key":"4213_CR53","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/0008-5472.CAN-21-0163","volume":"81","author":"C Enriquez","year":"2021","unstructured":"Enriquez C, Cancila V, Ferri R, Sulsenti R, Fischetti I, Milani M, et al. Castration-induced downregulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer. Cancer Res. 2021;81(16):4257\u201374.","journal-title":"Cancer Res"},{"key":"4213_CR54","doi-asserted-by":"publisher","first-page":"729498","DOI":"10.3389\/fcell.2021.729498","volume":"9","author":"Q Tang","year":"2021","unstructured":"Tang Q, Cheng B, Dai R, Wang R. The role of androgen receptor in cross talk between stromal cells and prostate cancer epithelial cells. Front Cell Dev Biol. 2021;9:729498.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"4213_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41559-020-1157-y","volume":"4","author":"Z Frankenstein","year":"2020","unstructured":"Frankenstein Z, Basanta D, Franco OE, Gao Y, Javier RA, Strand DW, et al. Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression. Nat Ecol Evol. 2020;4(6):870\u201384.","journal-title":"Nat Ecol Evol"},{"issue":"4","key":"4213_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000504247","volume":"64","author":"L Chen","year":"2020","unstructured":"Chen L, Yang F, Li T, Xiao P, Han Z-J, Shu L-F, et al. Extracellular histone promotes prostate cancer migration and epithelial-mesenchymal transition through NF-\u03baB-mediated inflammatory responses. Chemotherapy. 2020;64(4):177\u201386.","journal-title":"Chemotherapy"},{"key":"4213_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27628","author":"L Sun","year":"2024","unstructured":"Sun L, Tuo Z, Chen X, Wang H, Lyu Z, Li G. Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27628.","journal-title":"Heliyon"},{"issue":"3","key":"4213_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322.","journal-title":"Cancer Cell"},{"key":"4213_CR59","doi-asserted-by":"publisher","first-page":"119132","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Mousavi SM, Sheykholeslami PN, Fathi M, Saray MM, Aghebati-Maleki L, et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;284:119132.","journal-title":"Life Sci"},{"key":"4213_CR60","doi-asserted-by":"publisher","first-page":"119369","DOI":"10.1016\/j.lfs.2021.119369","volume":"275","author":"N Joshi","year":"2021","unstructured":"Joshi N, Hajizadeh F, Dezfouli EA, Zekiy AO, Afjadi MN, Mousavi SM, et al. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sci. 2021;275:119369.","journal-title":"Life Sci"},{"issue":"1","key":"4213_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12935-022-02528-8","volume":"22","author":"V Karpisheh","year":"2022","unstructured":"Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, MohammadpourSaray M, Barshidi A, Mohammadi H, et al. The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int. 2022;22(1):108.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"4213_CR62","doi-asserted-by":"publisher","first-page":"e002919","DOI":"10.1136\/jitc-2021-002919","volume":"9","author":"SK Subudhi","year":"2021","unstructured":"Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, et al. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021;9(10):e002919.","journal-title":"J Immunother Cancer"},{"key":"4213_CR63","doi-asserted-by":"publisher","first-page":"105997","DOI":"10.1016\/j.phrs.2021.105997","volume":"175","author":"L Lisi","year":"2022","unstructured":"Lisi L, Lacal PM, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: from the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacol Res. 2022;175:105997.","journal-title":"Pharmacol Res"},{"key":"4213_CR64","doi-asserted-by":"crossref","unstructured":"Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Roupr\u00eat M, Margulis V. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. 2020. Elsevier, pp 601\u2013e617.","DOI":"10.1016\/j.urolonc.2020.02.008"},{"issue":"1","key":"4213_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12885-020-07058-y","volume":"20","author":"MJ Bou-Dargham","year":"2020","unstructured":"Bou-Dargham MJ, Sha L, Sang Q-XA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer. 2020;20(1):572.","journal-title":"BMC Cancer"},{"key":"4213_CR66","doi-asserted-by":"crossref","unstructured":"de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune checkpoint blockade for prostate cancer: niche role or next breakthrough?. 2020: 1\u201318.","DOI":"10.1200\/EDBK_278853"},{"issue":"16","key":"4213_CR67","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"issue":"8","key":"4213_CR68","doi-asserted-by":"publisher","first-page":"T95","DOI":"10.1530\/ERC-21-0149","volume":"28","author":"JTW Kwon","year":"2021","unstructured":"Kwon JTW, Bryant RJ, Parkes EE. The tumor microenvironment and immune responses in prostate cancer patients. Endocr Relat Cancer. 2021;28(8):T95\u2013107.","journal-title":"Endocr Relat Cancer"},{"key":"4213_CR69","doi-asserted-by":"publisher","first-page":"840787","DOI":"10.3389\/fendo.2022.840787","volume":"13","author":"F Licitra","year":"2022","unstructured":"Licitra F, Giovannelli P, Di Donato M, Monaco A, Galasso G, Migliaccio A, et al. New insights and emerging therapeutic approaches in prostate cancer. Front Endocrinol. 2022;13:840787.","journal-title":"Front Endocrinol"},{"key":"4213_CR70","doi-asserted-by":"publisher","first-page":"627932","DOI":"10.3389\/fimmu.2021.627932","volume":"12","author":"SJ Paston","year":"2021","unstructured":"Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932.","journal-title":"Front Immunol"},{"issue":"4","key":"4213_CR71","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.maturitas.2011.04.012","volume":"69","author":"E Thara","year":"2011","unstructured":"Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011;69(4):296\u2013303.","journal-title":"Maturitas"},{"issue":"1","key":"4213_CR72","doi-asserted-by":"publisher","first-page":"e1486953","DOI":"10.1080\/2162402X.2018.1486953","volume":"8","author":"K Hagihara","year":"2019","unstructured":"Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, et al. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019;8(1):e1486953.","journal-title":"Oncoimmunology"},{"issue":"6","key":"4213_CR73","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","volume":"81","author":"PF Schellhammer","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013;81(6):1297\u2013302.","journal-title":"Urology"},{"issue":"8","key":"4213_CR74","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660\u20139.","journal-title":"Cell Res"},{"issue":"26","key":"4213_CR75","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"7","key":"4213_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/14712598.2011.573476","volume":"11","author":"CA Ramos","year":"2011","unstructured":"Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11(7):855\u201373.","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"4213_CR77","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76(14):1257\u201370.","journal-title":"Prostate"},{"issue":"7","key":"4213_CR78","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855\u201366.","journal-title":"Mol Ther"},{"key":"4213_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.125","volume-title":"A phase I clinical trial of PSMA-directed\/TGF\u03b2-insensitive CAR-T cells in metastatic castration-resistant prostate cancer","author":"V Narayan","year":"2021","unstructured":"Narayan V, Barber-Rotenberg J, Fraietta J, Hwang W-T, Lacey SF, Plesa G, et al. A phase I clinical trial of PSMA-directed\/TGF\u03b2-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. American Society of Clinical Oncology; 2021."},{"issue":"2","key":"4213_CR80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/uro2020010","volume":"2","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Campbell BK, Stylli SS, Corcoran NM, Hovens CM. The prostate cancer immune microenvironment, biomarkers and therapeutic intervention. Uro. 2022;2(2):74\u201392.","journal-title":"Uro"},{"key":"4213_CR81","volume-title":"CheckMate 9KD Arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","author":"K Fizazi","year":"2021","unstructured":"Fizazi K, Gonz\u00e1lez Mella P, Castellano D, Minatta JN, Rezazadeh A, Shaffer DR, et al. CheckMate 9KD Arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-na\u00efve metastatic castration-resistant prostate cancer. American Society of Clinical Oncology; 2021."},{"issue":"9","key":"4213_CR82","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41419-020-02973-1","volume":"11","author":"X Long","year":"2020","unstructured":"Long X, Hou H, Wang X, Liu S, Diao T, Lai S, et al. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. Cell Death Dis. 2020;11(9):779.","journal-title":"Cell Death Dis"},{"issue":"3","key":"4213_CR83","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/jcm9030670","volume":"9","author":"M Krebs","year":"2020","unstructured":"Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, et al. miR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro. J Clin Med. 2020;9(3):670.","journal-title":"J Clin Med"},{"key":"4213_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.142","volume-title":"Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650)","author":"P Sharma","year":"2019","unstructured":"Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). American Society of Clinical Oncology; 2019."},{"issue":"4","key":"4213_CR85","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Fl\u00e9chon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38(4):489-499. e483.","journal-title":"Cancer Cell"},{"issue":"9","key":"4213_CR86","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.3390\/ijms22094712","volume":"22","author":"V de Ruiz Porras","year":"2021","unstructured":"de Ruiz Porras V, Pardo JC, Notario L, Etxaniz O, Font A. Immune checkpoint inhibitors: a promising treatment option for metastatic castration-resistant prostate cancer? Int J Mol Sci. 2021;22(9):4712.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4213_CR87","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/geno.1999.5930","volume":"60","author":"V Ling","year":"1999","unstructured":"Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M. Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics. 1999;60(3):341\u201355.","journal-title":"Genomics"},{"key":"4213_CR88","doi-asserted-by":"crossref","unstructured":"Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy. 2020:7\u201332.","DOI":"10.1007\/978-981-15-3266-5_2"},{"issue":"43","key":"4213_CR89","doi-asserted-by":"publisher","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","volume":"271","author":"JL Greene","year":"1996","unstructured":"Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, et al. Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271(43):26762\u201371.","journal-title":"J Biol Chem"},{"issue":"12","key":"4213_CR90","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852\u201363.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"4213_CR91","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7\u20131 (CD80) and B7\u20132 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793\u2013801.","journal-title":"Immunity"},{"issue":"3","key":"4213_CR92","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185(3):393\u2013404.","journal-title":"J Exp Med"},{"issue":"10","key":"4213_CR93","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.4049\/jimmunol.164.10.5319","volume":"164","author":"EL Masteller","year":"2000","unstructured":"Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol. 2000;164(10):5319\u201327.","journal-title":"J Immunol"},{"issue":"5397","key":"4213_CR94","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","volume":"282","author":"K-M Lee","year":"1998","unstructured":"Lee K-M, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282(5397):2263\u20136.","journal-title":"Science"},{"issue":"1","key":"4213_CR95","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1084\/jem.181.1.351","volume":"181","author":"H Schneider","year":"1995","unstructured":"Schneider H, Prasad K, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med. 1995;181(1):351\u20135.","journal-title":"J Exp Med"},{"key":"4213_CR96","first-page":"111","volume":"4","author":"N Beyersdorf","year":"2015","unstructured":"Beyersdorf N, Kerkau T, H\u00fcnig T. CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther. 2015;4:111\u201322.","journal-title":"Immunotargets Ther"},{"key":"4213_CR97","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","volume":"14","author":"MM Hossen","year":"2023","unstructured":"Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023;14:1198365.","journal-title":"Front Immunol"},{"issue":"1","key":"4213_CR98","first-page":"58","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood J Am Soc Hematol. 2018;131(1):58\u201367.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"4213_CR99","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973\u201388.","journal-title":"Immunity"},{"key":"4213_CR100","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"H Fs","year":"2010","unstructured":"Fs H. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"issue":"21","key":"4213_CR101","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"19","key":"4213_CR102","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"2","key":"4213_CR103","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans P, Bundred NJ, Foidart J-M, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135\u201346.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4213_CR104","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"key":"4213_CR105","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"issue":"26","key":"4213_CR106","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"4213_CR107","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12253-016-0180-4","volume":"23","author":"L Karabon","year":"2017","unstructured":"Karabon L, Tupikowski K, Tomkiewicz A, Partyka A, Pawlak-Adamska E, Wojciechowski A, et al. Is the genetic background of co-stimulatory CD28\/CTLA-4 pathway the risk factor for prostate cancer? Pathol Oncol Res. 2017;23(4):837\u201343.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"4213_CR108","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00262-012-1330-5","volume":"62","author":"SJAM Santegoets","year":"2013","unstructured":"Santegoets SJAM, Stam AGM, Lougheed SM, Gall H, Scholten PET, Reijm M, et al. T cell profiling reveals high CD4+ CTLA-4+ T cell frequency as dominant predictor for survival after prostate GVAX\/ipilimumab treatment. Cancer Immunol Immunother. 2013;62(2):245\u201356.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"4213_CR109","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/2326-6066.CIR-14-0227","volume":"3","author":"SS Kwek","year":"2015","unstructured":"Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, et al. Preexisting levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab. Cancer Immunol Res. 2015;3(9):1008\u201316.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"4213_CR110","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.4049\/jimmunol.1201529","volume":"189","author":"SS Kwek","year":"2012","unstructured":"Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012;189(7):3759\u201366.","journal-title":"J Immunol"},{"issue":"8","key":"4213_CR111","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1073\/pnas.0813175106","volume":"106","author":"H Chen","year":"2009","unstructured":"Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, et al. Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-\u03b3 levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009;106(8):2729\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"4213_CR112","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/pros.22858","volume":"74","author":"EN Klyushnenkova","year":"2014","unstructured":"Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander RB. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate. 2014;74(14):1423\u201332.","journal-title":"Prostate"},{"issue":"238","key":"4213_CR113","doi-asserted-by":"publisher","first-page":"238ra270","DOI":"10.1126\/scitranslmed.3008211","volume":"6","author":"E Cha","year":"2014","unstructured":"Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti\u2013CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra270-238ra270.","journal-title":"Sci Transl Med"},{"issue":"26","key":"4213_CR114","doi-asserted-by":"publisher","first-page":"15074","DOI":"10.1073\/pnas.96.26.15074","volume":"96","author":"ED Kwon","year":"1999","unstructured":"Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA. 1999;96(26):15074\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"4213_CR115","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13(6):1810\u20135.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4213_CR116","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-13-0193","volume":"2","author":"JN Graff","year":"2014","unstructured":"Graff JN, Puri S, Bifulco CB, Fox BA, Beer TM. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res. 2014;2(5):399\u2013403.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4213_CR117","first-page":"242","volume":"25","author":"JA Garcia","year":"2011","unstructured":"Garcia JA, Dreicer R. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology. 2011;25(3):242.","journal-title":"Oncology"},{"issue":"9","key":"4213_CR118","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1073\/pnas.0712269105","volume":"105","author":"M Fasso","year":"2008","unstructured":"Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)\/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci USA. 2008;105(9):3509\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"4213_CR119","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.4049\/jimmunol.1201744","volume":"189","author":"BM Olson","year":"2012","unstructured":"Olson BM, Jankowska-Gan E, Becker JT, Vignali DAA, Burlingham WJ, McNeel DG. Human prostate tumor antigen\u2013specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012;189(12):5590\u2013601.","journal-title":"J Immunol"},{"issue":"11","key":"4213_CR120","doi-asserted-by":"publisher","first-page":"e5620","DOI":"10.1590\/1414-431x20165620","volume":"49","author":"TJ Mai","year":"2016","unstructured":"Mai TJ, Ma R, Li Z, Bi SC. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer. Braz J Med Biol Res. 2016;49(11):e5620.","journal-title":"Braz J Med Biol Res"},{"issue":"9","key":"4213_CR121","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60(9):2444\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"4213_CR122","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.imlet.2007.07.019","volume":"113","author":"N Li","year":"2007","unstructured":"Li N, Qin H, Li X, Zhou C, Wang D, Ma W, et al. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Immunol Lett. 2007;113(2):90\u20138.","journal-title":"Immunol Lett"},{"issue":"1","key":"4213_CR123","first-page":"439235","volume":"2012","author":"K Youlin","year":"2012","unstructured":"Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z. Combination immunotherapy with 4\u20101BBL and CTLA\u20104 blockade for the treatment of prostate cancer. J Immunol Res. 2012;2012(1):439235.","journal-title":"J Immunol Res"},{"issue":"5","key":"4213_CR124","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3816\/CGC.2007.n.017","volume":"5","author":"MR Theoret","year":"2007","unstructured":"Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti\u2013CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2007;5(5):347\u201350.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"4213_CR125","doi-asserted-by":"publisher","first-page":"e002254","DOI":"10.1136\/jitc-2020-002254","volume":"9","author":"M Sinha","year":"2021","unstructured":"Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, et al. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021;9(5):e002254.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4213_CR126","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00262-021-02915-6","volume":"70","author":"K Witt","year":"2021","unstructured":"Witt K, Evans-Axelsson S, Lundqvist A, Johansson M, Bjartell A, Hellsten R. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunol Immunother. 2021;70(11):3155\u201366.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"4213_CR127","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4149\/neo_2014_081","volume":"61","author":"F Li","year":"2014","unstructured":"Li F, Guo Z, Yu H, Zhang X, Si T, Liu C, et al. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model. Neoplasma. 2014;61(6):659\u201371.","journal-title":"Neoplasma"},{"issue":"2","key":"4213_CR128","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6(2):189\u2013200.","journal-title":"Cancer Immunol Res"},{"key":"4213_CR129","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.09.24313308","author":"CR Ager","year":"2025","unstructured":"Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, et al. Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer. MedRxiv. 2025. https:\/\/doi.org\/10.1101\/2024.09.09.24313308.","journal-title":"MedRxiv"},{"key":"4213_CR130","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3389\/fonc.2020.01381","volume":"10","author":"JN Graff","year":"2020","unstructured":"Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, et al. Phase II study of ipilimumab in men with metastatic prostate cancer with an incomplete response to androgen deprivation therapy. Front Oncol. 2020;10:1381.","journal-title":"Front Oncol"},{"issue":"5","key":"4213_CR131","doi-asserted-by":"publisher","first-page":"e233496","DOI":"10.1136\/bcr-2019-233496","volume":"13","author":"D Henderson","year":"2020","unstructured":"Henderson D, Eslamian G, Poon D, Crabb S, Jones R, Sankey P, et al. Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Reports CP. 2020;13(5):e233496.","journal-title":"BMJ Case Reports CP"},{"issue":"17","key":"4213_CR132","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"key":"4213_CR133","unstructured":"Clancy E. ACS report shows prostate cancer on the rise, cervical cancer on the decline. Renal & Urology News. 2023:NA-NA."},{"issue":"12","key":"4213_CR134","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","volume":"35","author":"S van Wilpe","year":"2024","unstructured":"van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, et al. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Ann Oncol. 2024;35(12):1126\u201337.","journal-title":"Ann Oncol"},{"issue":"2","key":"4213_CR135","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","volume":"69","author":"L Fong","year":"2009","unstructured":"Fong L, Kwek SS, O\u2019Brien S, Kavanagh B, McNeel DG, Weinberg V, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69(2):609\u201315.","journal-title":"Cancer Res"},{"issue":"1","key":"4213_CR136","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38(1):541\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"4213_CR137","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.","journal-title":"Cell"},{"issue":"2","key":"4213_CR138","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"4213_CR139","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ucl.2020.07.010","volume":"47","author":"D Chakravarty","year":"2020","unstructured":"Chakravarty D, Huang L, Kahn M, Tewari AK. Immunotherapy for metastatic prostate cancer: current and emerging treatment options. Urol Clin North Am. 2020;47(4):487\u2013510.","journal-title":"Urol Clin North Am"},{"key":"4213_CR140","doi-asserted-by":"publisher","first-page":"915094","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ni Y, Liang X, Lin Y, An B, He X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol. 2022;13:915094.","journal-title":"Front Immunol"},{"issue":"7","key":"4213_CR141","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.crad.2024.02.015","volume":"79","author":"S Shukla","year":"2024","unstructured":"Shukla S, Karbhari A, Rastogi S, Agarwal U, Rai P, Mahajan A. Bench-to-bedside imaging in brain metastases: a road to precision oncology. Clin Radiol. 2024;79(7):485\u2013500.","journal-title":"Clin Radiol"},{"key":"4213_CR142","doi-asserted-by":"publisher","first-page":"117141","DOI":"10.1016\/j.ejmech.2024.117141","volume":"283","author":"B Cheng","year":"2025","unstructured":"Cheng B, Lv J, Xiao Y, Song C, Chen J, Shao C. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024). Eur J Med Chem. 2025;283:117141.","journal-title":"Eur J Med Chem"},{"key":"4213_CR143","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omto.2023.04.007","volume":"29","author":"M Lin","year":"2023","unstructured":"Lin M, Sun X, Lv L. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Mol Ther Oncol. 2023;29:91\u2013106.","journal-title":"Mol Ther Oncol"},{"issue":"9","key":"4213_CR144","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrclinonc.2011.72","volume":"8","author":"G Di Lorenzo","year":"2011","unstructured":"Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011;8(9):551\u201361.","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"4213_CR145","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.3390\/cancers13194757","volume":"13","author":"M Movassaghi","year":"2021","unstructured":"Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I. Overcoming immune resistance in prostate cancer: challenges and advances. Cancers. 2021;13(19):4757.","journal-title":"Cancers"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04213-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:47Z","timestamp":1781877887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04213-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":145,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04213-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All of the authors consent for this article publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}